MAIA Biotechnology’s stock experienced a pronounced decline in premarket trading on Tuesday, falling 29% to $1.47 following the company’s announcement of a $30 million public offering conducted at a substantial discount.
On Monday, MAIA sold 20 million shares at $1.50 each, a price that the company said represents a 27.5% discount to the stock’s prior closing level. The scale of the issuance is notable relative to the company’s share count, with MAIA reporting 38.7 million outstanding shares as of Monday in the offering prospectus.
The transaction was led by investors that specialize in the healthcare sector, with participation from existing shareholders, according to the company’s statement. Konik Capital Partners served as the sole book-running manager for the offering.
MAIA indicated that the net proceeds from the placement will be directed toward funding clinical trials and to support working capital and other general corporate purposes. The company did not provide additional detail in its announcement about the specific trials or a timeline for spending the proceeds.
Investors reacted quickly to the terms of the sale, pushing the stock down sharply in premarket trade on Tuesday as the market priced in the dilutive impact and the steep markdown to the prior close. The number of shares issued - 20 million - and the previously reported 38.7 million shares outstanding show that the new offering represents a material increase in the company’s share base.
This financing step will provide MAIA with cash intended to underwrite near-term clinical activity and corporate needs, while also expanding the company’s outstanding share count. Konik Capital Partners’ role as sole book-running manager was confirmed in the prospectus filed alongside the offering details.
Contextual note - The company stated the use of proceeds and the composition of investors in the offering, but did not disclose additional operational or clinical specifics within the announcement accompanying the financing.